PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function

BACKGROUND: An important portion of asthmatics do not respond to current therapies. Thus, the need for new therapeutic drugs is urgent. We have demonstrated a critical role for PARP in experimental asthma. Olaparib, a PARP inhibitor, was recently introduced in clinical trials against cancer. The obj...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghonim, Mohamed A, Pyakurel, Kusma, Ibba, Salome V, Al-Khami, Amir A, Wang, Jeffrey, Rodriguez, Paulo, Rady, Hamada F, El-Bahrawy, Ali H, Lammi, Matthew R, Mansy, Moselhy S, Al-Ghareeb, Kamel, Ramsay, Alistair, Ochoa, Augusto, Naura, Amarjit S, Boulares, A Hamid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501284/
https://www.ncbi.nlm.nih.gov/pubmed/26169874
http://dx.doi.org/10.1186/s12967-015-0583-0

Ejemplares similares

Ejemplares similares